A single nucleotide polymorphism in cBIM is associated with a slower achievement of major molecular response in chronic myeloid leukaemia treated with imatinib

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Augis, Vanessa ^a,b   Airiau, Kelly ^a   Josselin, Marina ^a   Turcq, Béatrice ^a   Mahon, François Xavier ^a,b   Belloc, Francis ^a,b  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; BIM PROTEIN; IMATINIB; MESSENGER RNA;

ADOLESCENT; ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; BIM GENE; CANCER RESISTANCE; CASE CONTROL STUDY; CHILD; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FRANCE; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC RISK; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; MUTATION RATE; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLELES; ANTINEOPLASTIC AGENTS; APOPTOSIS REGULATORY PROTEINS; BENZAMIDES; BIOMARKERS, PHARMACOLOGICAL; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION; GENE FREQUENCY; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKOCYTES, MONONUCLEAR; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION RATE; PIPERAZINES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS; PYRIMIDINES; RNA, MESSENGER;

EID: 84892378299     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078582     Document Type: Article

References (29)

1. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, et al. (2009) Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 27: 6041-6051.
2. Lahaye T, Riehm B, Berger U, Paschka P, Muller MC, et al. (2005) Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Cancer 103: 1659-1669.
3. Baran Y, Ural AU, Gunduz U (2007) Mechanisms of cellular resistance to imatinib in human chronic myeloid leukemia cells. Hematology: 1.
4. Deininger MW, Goldman JM, Lydon N, Melo JV (1997) The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 90: 3691-3698.
5. Shinjyo T, Kuribara R, Inukai T, Hosoi H, Kinoshita T, et al. (2001) Downregulation of Bim, a proapoptotic relative of Bcl-2, is a pivotal step in cytokine-initiated survival signaling in murine hematopoietic progenitors. Mol Cell Biol 21: 854-864.
6. Kuribara R, Honda H, Matsui H, Shinjyo T, Inukai T, et al. (2004) Roles of Bim in apoptosis of normal and Bcr-Abl-expressing hematopoietic progenitors. Mol Cell Biol 24: 6172-6183.
7. Belloc F, Moreau-Gaudry F, Uhalde M, Cazalis L, Jeanneteau M, et al. (2007) Imatinib and nilotinib induce apoptosis of chronic myeloid leukemia cells through a Bim-dependant pathway modulated by cytokines. Cancer Biol Ther 6: 912-919.
8. Ng KP, Hillmer AM, Chuah CT, Juan WC, Ko TK, et al. (2012) A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med 18: 521-528.
9. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, et al. (2006) Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108: 28-37.
10. Branford S, Hughes T (2006) Detection of BCR-ABL mutations and resistance to imatinib mesylate. Methods Mol Med 125: 93-106.
11. O'Connor L, Strasser A, O'Reilly LA, Hausmann G, Adams JM, et al. (1998) Bim: a novel member of the Bcl-2 family that promotes apoptosis. EMBO J 17: 384-395.
12. Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, et al. (2000) Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 96: 1070-1079.
13. SNPstats software. Available : http://bioinfo.iconcologia.net/snpstats/ start.htm. Accessed 2012.
14. Sole X, Guino E, Valls J, Iniesta R, Moreno V (2006) SNPStats: a web tool for the analysis of association studies. Bioinformatics 22: 1928-1929.
15. International HapMap project website. Available http://hapmap.ncbi.nlm. nih.gov/ Accessed 2008
16. dbSNP website. Available http://www.ncbi.nlm.nih.gov/SNP/. Accessed 2008
17. Egle A, Harris AW, Bouillet P, Cory S (2004) Bim is a suppressor of Mycinduced mouse B cell leukemia. Proc Natl Acad Sci U S A 101: 6164-6169.
18. Mestre-Escorihuela C, Rubio-Moscardo F, Richter JA, Siebert R, Climent J, et al. (2007) Homozygous deletions localize novel tumor suppressor genes in Bcell lymphomas. Blood 109: 271-280.
19. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, et al. (2007) A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 315: 525-528.
20. Duan J, Wainwright MS, Comeron JM, Saitou N, Sanders AR, et al. (2003) Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum Mol Genet 12: 205-216.
21. Sauna ZE, Kimchi-Sarfaty C, Ambudkar SV, Gottesman MM (2007) Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer. Cancer Res 67: 9609-9612.
22. Dulucq S, Bouchet S, Turcq B, Lippert E, Etienne G, et al. (2008) Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 112: 2024-2027.
23. Bermano G, Pagmantidis V, Holloway N, Kadri S, Mowat NA, et al. (2007) Evidence that a polymorphism within the 3'UTR of glutathione peroxidase 4 is functional and is associated with susceptibility to colorectal cancer. Genes Nutr 2: 225-232.
24. Xiao C, Srinivasan L, Calado DP, Patterson HC, Zhang B, et al. (2008) Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol 9: 405-414.
25. Kelly JL, Novak AJ, Fredericksen ZS, Liebow M, Ansell SM, et al. (2010) Germline variation in apoptosis pathway genes and risk of non-Hodgkin's lymphoma. Cancer Epidemiol Biomarkers Prev 19: 2847-2858.
26. SNP@promoter website. Available : http://variome.kobic.re.kr/ SNPatPromoter. Accessed 2008.
27. U M, Miyashita T, Shikama Y, Tadokoro K, Yamada M (2001) Molecular cloning and characterization of six novel isoforms of human Bim, a member of the proapoptotic Bcl-2 family. FEBS Lett 509: 135-141.
28. Miao J, Chen GG, Yun JP, Chun SY, Zheng ZZ, et al. (2007) Identification and characterization of BH3 domain protein Bim and its isoforms in human hepatocellular carcinomas. Apoptosis 12: 1691-1701.
29. Airiau K, Mahon FX, Josselin M, Jeanneteau M, Turcq B, et al. (2012) ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib. Exp Hematol 40: 367-378 e362.